Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.55 -1.3%	$10.45	$4.93 ▼ $14.44	$831.45M	0.8	1.14 million shs	670,383 shs
DMAC DiaMedica Therapeutics	$5.93 -1.2%	$4.38	$3.19 ▼ $6.82	$310.13M	1.25	366,484 shs	128,988 shs
GPCR Structure Therapeutics	$19.37 +4.3%	$19.28	$13.22 ▼ $45.37	$1.07B	-1.89	911,092 shs	759,561 shs
RCUS Arcus Biosciences	$10.50 +4.0%	$9.22	$6.50 ▼ $18.98	$1.07B	0.89	809,844 shs	593,806 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+2.54%	-8.33%	-13.26%	+26.21%	+57.91%
DMAC DiaMedica Therapeutics	+3.99%	0.00%	+32.16%	+48.15%	+62.16%
GPCR Structure Therapeutics	-1.22%	-3.08%	+2.43%	-24.67%	-53.89%
RCUS Arcus Biosciences	+0.45%	+0.25%	+8.84%	+14.86%	-42.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8804 of 5 stars	3.5	1.0	4.7	2.8	0.8	0.6
DMAC DiaMedica Therapeutics	1.6176 of 5 stars	3.5	0.0	0.0	2.5	1.7	0.0
GPCR Structure Therapeutics	2.3349 of 5 stars	3.5	3.0	0.0	0.9	1.7	0.6
RCUS Arcus Biosciences	2.0891 of 5 stars	3.4	3.0	0.0	1.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.00	Buy	$44.00	360.73% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$12.33	107.98% Upside
GPCR Structure Therapeutics	3.00	Buy	$75.71	290.88% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	101.46% Upside

Current Analyst Ratings Breakdown

Latest DMAC, RCUS, AVXL, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
RCUS Arcus Biosciences	$258M	4.33	N/A	N/A	$5.16 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
DMAC DiaMedica Therapeutics	-$24.44M	-$0.69	N/A	N/A	N/A	N/A	-78.99%	-69.94%	N/A
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	N/A
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)

Latest DMAC, RCUS, AVXL, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	8.93	8.93
DMAC DiaMedica Therapeutics	N/A	7.55	7.55
GPCR Structure Therapeutics	N/A	20.48	20.48
RCUS Arcus Biosciences	0.18	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
DMAC DiaMedica Therapeutics	10.12%
GPCR Structure Therapeutics	91.78%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
DMAC DiaMedica Therapeutics	7.30%
GPCR Structure Therapeutics	5.60%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable

DMAC, RCUS, AVXL, and GPCR Headlines

Recent News About These Companies

Gilead Sciences Inc. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS)

August 19 at 7:41 AM | marketbeat.com

Jim Cramer on Arcus Biosciences: “Let This Be Your Speculation”

August 16, 2025 | finance.yahoo.com

Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $21.14

August 15, 2025 | americanbankingnews.com

Cramer's Lightning Round: Uranium Energy is a buy

August 14, 2025 | msn.com

Leerink Partnrs Expects Lower Earnings for Arcus Biosciences

August 12, 2025 | americanbankingnews.com

HC Wainwright Analysts Lower Earnings Estimates for RCUS

August 12, 2025 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 12, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings

August 11, 2025 | marketbeat.com

Wedbush Predicts Arcus Biosciences' Q3 Earnings (NYSE:RCUS)

August 11, 2025 | americanbankingnews.com

Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst

August 11, 2025 | marketbeat.com

Leerink Partnrs Has Negative Estimate for RCUS Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Forecasts Lower Earnings for Arcus Biosciences

August 11, 2025 | marketbeat.com

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

August 10, 2025 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Wedbush Decreases Earnings Estimates for Arcus Biosciences

August 9, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Price Target Lowered to $25.00 at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Gilead hands back one Arcus cancer candidate from $725M deal

August 7, 2025 | fiercebiotech.comF

Arcus (RCUS) Q2 Revenue Jumps 310%

August 6, 2025 | fool.com

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

August 6, 2025 | zacks.com

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

August 6, 2025 | gurufocus.com

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

August 6, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, RCUS, AVXL, and GPCR Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.55 -0.13 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$9.65 +0.10 (+1.05%)

As of 05:28 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

DiaMedica Therapeutics NASDAQ:DMAC

$5.93 -0.07 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.11 +0.18 (+3.02%)

As of 06:38 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Structure Therapeutics NASDAQ:GPCR

$19.37 +0.80 (+4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$19.38 +0.00 (+0.03%)

As of 06:30 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Arcus Biosciences NYSE:RCUS

$10.50 +0.41 (+4.01%)

Closing price 03:59 PM Eastern

Extended Trading

$10.56 +0.07 (+0.62%)

As of 07:41 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time